Dr. Curtis Schreiber led the study at CMH’s Missouri Memory Center, which was one of only 12 clinics nationwide selected to ...

In a document (PDF) recapping a February stakeholder call that was first obtained by Stat, the agency estimates that per member per month spending on Leqembi will rise from $1.67 in 2024 to $4.67 ...

With concerns growing over the burden Leqembi could impose on healthcare infrastructure, Eisai and Biogen have trotted out data for an under-the-skin version of the Alzheimer’s disease dr ...

Leqembi got its initial accelerated approval in January with limited Medicare coverage. Now, the Centers for Medicare & Medicaid Services has opened a registry as a reimbursement pathway.

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has shown continued benefit over four years, according ...

Leqembi targets the amyloid protein that builds up in the form of plaques in the brains of people with Alzheimer's disease, said Dr. Judith Heidebrink, a neurologist at Michigan Medicine and ...

Leqembi is priced at about $26,500 for a year’s supply of IVs every two weeks. The vast majority of Americans with Alzheimer’s get their health coverage through Medicare.

Leqembi is priced at about $26,500 for a year’s supply of IVs every two weeks. The vast majority of Americans with Alzheimer’s get their health coverage through Medicare.

Leqembi, a drug that can help treat adult patients with Alzheimer’s, was given traditional approval by the FDA on Thursday. It was first approved in January for clinical trials.

Leqembi is priced at about $26,500 for a year’s supply of IVs every two weeks. The vast majority of Americans with Alzheimer’s get their health coverage through Medicare.

Leqembi is priced at about $26,500 for a year’s supply of IVs every two weeks. The vast majority of Americans with Alzheimer’s get their health coverage through Medicare.